Brief Summary
The primary objective of this study is to compare progression-free survival (PFS) in participants who receive sotorasib with platinum doublet chemotherapya cancer treatment that uses drugs to kill or slow the growth of cancer cells, while minimising damage to healthy cells versus participants who receive pembrolizumab with platinum doublet chemotherapy.
Intervention / Treatment
- Drug: Sotorasib
- Drug: Pembrolizumab
Inclusion Criteria:
- Histologically or cytologically confirmed diagnosisthe process of identifying a disease based on signs and symptoms, patient history and medical test results of nonsquamous stage IV or advancedat a late stage, far along Stage IIIB or IIIC NSCLC with KRAS p. G12C mutation and negative for PD-L1 expression by central testing or local laboratory testing confirmed through central testing
- No history of systemic anticancer therapy in metastatic/non-curable settings
- Eastern Cooperative Oncologythe study, diagnosis and treatment of cancer Group (ECOG) ≤ 1.